Small Molecule Inhibitors for Selective MASP Protein Activity Control
Solution Overview
Problem
Current understanding of complement activation mechanisms is limited, particularly in how MASP proteins combine to activate the lectin and classical pathways, and there is a need for selective inhibitors to manage conditions like ischemia reperfusion injury and inflammatory disorders.
Innovation Solution
A method for screening small molecules to inhibit MASP protein activity by contacting MASP proteins with candidate inhibitors in the presence of mannose-binding lectin or ficolin collagen-like binding domains and Ca2+, determining binding affinity and activity levels to identify effective inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MASP proteins are activated to fight infections, then immune defense capability is improved, but tissue damage and inflammatory disorders are worsened
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that selectively bind to MASP proteins to inhibit their activation. These compounds act as mediators between the lectin pathway components (MBL/ficolins) and the complement cascade, preventing excessive complement activation and downstream tissue damage while preserving essential immune defense functions
Solution Approach 2:
The patent modifies the activation parameters of the complement system by introducing compounds that change the binding affinity and catalytic activity of MASP proteins. By altering these biochemical parameters, the system achieves selective inhibition of pathogenic complement activation while maintaining physiological immune responses
2Productivity
If broad complement activation occurs to eliminate pathogens, then pathogen clearance is improved, but selectivity and avoidance of self-damage are worsened
Solution Approach 1:
The patent applies local quality control by designing MASP inhibitors that specifically target the lectin pathway's protease activity without affecting other complement pathways or immune functions. This localized intervention allows pathogen clearance through intact recognition mechanisms while preventing harmful activation in self-tissues
Solution Approach 2:
Small molecule compounds serve as intermediary regulators that modulate MASP activity in a controlled manner. These intermediaries provide selective inhibition at the level of protease activation, allowing the immune system to maintain pathogen clearance efficiency while avoiding self-damage through regulated complement cascades
3Object-affected harmful factors
If MASP activity is inhibited to reduce tissue damage, then inflammatory response is controlled, but immune defense capability is worsened
Solution Approach 1:
The patent employs partial inhibition of MASP activity rather than complete blockade. The small molecule compounds achieve sufficient inhibition of pathogenic complement activation to prevent tissue damage, while leaving residual MASP activity intact to maintain essential immune defense functions against infections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of small molecules that can disrupt MASP protein activity, potentially treating conditions such as ischemia reperfusion injury and inflammatory disorders by selectively inhibiting complement activation.
Implementation Method 1
contacting MASP proteins with candidate inhibitors in the presence of mannose-binding lectin or ficolin collagen-like binding domains and Ca2+
Implementation Method 2
contacting MASP proteins with candidate inhibitors in the presence of mannose-binding lectin or ficolin collagen-like binding domains and Ca2+
Data Source
AI summary
This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.